Off-Label Promotion: FDA Court Filing Says It Must Retain Enforcement Flexibility, Citing Harms From Premarin And ESAs
Executive Summary
FDA adamantly rejected Allergan's proposals to loosen restrictions on off-label drug promotion in a further response to Allergan's suit against the agency